Colchicine in Coronary Artery Bypass Graft (CABG)

Study of Anti-inflammatory Treatment With Colchicine in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery to Reduce Reperfusion Damage

There is evidence that inflammatory processes may play a key role during surgical myocardial reperfusion. The hypothesis of this study is that colchicine, an anti-inflammatory agent, may lead to reduction in periprocedural infarct size, when administered during elective coronary artery bypass graft surgery.

Inclusion Criteria:

• The study will enroll patients 18 years old or older who are eligible to undergo CABG surgery.

Exclusion Criteria:

Excluded are patients:

• with age > 80 years old
• scheduled for concomitant valve surgery
• scheduled for coronary surgery without cardiopulmonary bypass
• with peripheral vascular disease affecting the upper limbs
• with acute coronary syndrome within the previous 4 weeks
• on inotropic or mechanical circulatory support before induction of anaesthesia
• with any disorder that could potentially increase preoperative cTnI concentrations (eg, percutaneous coronary intervention within the previous 6 weeks)
• with active inflammatory diseases, infectious diseases or known malignancy
• under treatment with corticosteroids, anti-inflammatory agents or disease modifying agents
• with known hypersensitivity-allergy to colchicine
• under chronic treatment with colchicine
• with severe renal failure (eGFR < 35 ml/min/1.73 m2)
• with hepatic failure (Child - Pugh class B or C)